Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ICT Approved to Start US Trials of CD-19 CAR-T for Lymphoma

publication date: Dec 4, 2019

Innovative Cellular Therapeutics (ICT), a Shanghai-US CAR-T company, reported the US FDA approved its IND for ICTCAR014, a next gen CD19-targeting CAR-T cell therapy. ICT said ICTCAR014 expresses a dominant negative PD-1 protein to block immunosuppression by cancer cells. The company expects the US trial will test ICTCAR014 in patients with relapsed or refractory non-Hodgkin lymphoma, including patients with PD-L1 positive tumors. ICT, which has already completed a China trial of ICTCAR014, plans to move its products rapidly through proof-of-concept trials in China and then expand into US and global development. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020